Pei Ouyang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pei Ouyang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Bo Peng
National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan SANS Neuroscience Center, Fudan University
2 shared publications - Xiaoyu Li
National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan SANS Neuroscience Center, Fudan University
2 shared publications - Yanxia Rao
National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan SANS Neuroscience Center, Fudan University
2 shared publications - Yuxin Li
National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan SANS Neuroscience Center, Fudan University
2 shared publications - Baozhi Yang
Department of Neurology, Zhongshan Hospital, Laboratory Animal Center, Fudan University
1 shared publication - Chunkang Chang
Department of Hematology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 15
In vivo virus-free lineage tracing and live imaging reveal that NeuroD1 does not reprogram microglia into neurons
In situ glia-to-neuron conversion induced by a single transcription factor is a promising regenerative strategy for treating central nervous system injuries and neurodegenerative diseases. Previous studies reported that NeuroD1 can induce microglia-to-neuron cross-lineage conversion and improve recovery after brain injury. However, these findings remain controversial. To examine the ability of NeuroD1 in inducing microglia-to-neuron conversion, we employed virus-free genetic lineage tracing systems in mice to specifically induce NeuroD1 expression in microglia and track the cell fate of NeuroD1-expressing cells at multiple timepoints. Meanwhile, we longitudinally monitored NeuroD1-expressing microglia via two-photon imaging and characterized their transcriptional profile by single-cell RNA sequencing. All observations across these methods revealed that NeuroD1-expressing cells retained their microglia identity and cannot convert into neurons, under either physiological or injury conditions. Instead, sustained expression of NeuroD1 induced microglial apoptosis in vivo. Collectively, our findings provide strong evidence that NeuroD1 is not sufficient to induce microglia-to-neuron conversion. This study further highlights the importance of rigorous lineage tracing and cell fate mapping strategies for validating in situ glia-to-neuron conversion.
- 16 October 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 15
Open AccessIn vivo virus-free lineage tracing and live imaging reveal that NeuroD1 does not reprogram microglia into neurons
In situ glia-to-neuron conversion induced by a single transcription factor is a promising regenerative strategy for treating central nervous system injuries and neurodegenerative diseases. Previous studies reported that NeuroD1 can induce microglia-to-neuron cross-lineage conversion and improve recovery after brain injury. However, these findings remain controversial. To examine the ability of NeuroD1 in inducing microglia-to-neuron conversion, we employed virus-free genetic lineage tracing systems in mice to specifically induce NeuroD1 expression in microglia and track the cell fate of NeuroD1-expressing cells at multiple timepoints. Meanwhile, we longitudinally monitored NeuroD1-expressing microglia via two-photon imaging and characterized their transcriptional profile by single-cell RNA sequencing. All observations across these methods revealed that NeuroD1-expressing cells retained their microglia identity and cannot convert into neurons, under either physiological or injury conditions. Instead, sustained expression of NeuroD1 induced microglial apoptosis in vivo. Collectively, our findings provide strong evidence that NeuroD1 is not sufficient to induce microglia-to-neuron conversion. This study further highlights the importance of rigorous lineage tracing and cell fate mapping strategies for validating in situ glia-to-neuron conversion.
- Top Cited Papers
- 10 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6756) , eadr1015
Microglia replacement halts the progression of microgliopathy in mice and humans
Colony-stimulating factor 1 receptor ( CSF1R ) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.
- 10 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6756) , eadr1015
Top Cited PapersMicroglia replacement halts the progression of microgliopathy in mice and humans
Colony-stimulating factor 1 receptor ( CSF1R ) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.